Crossmark

What We Can Learn from Current Inflammatory Bowel Disease (IBD) Biological Therapy—Dose Regimen and Others

Crossref DOI link: https://doi.org/10.1007/s40495-019-00180-x

Published Online: 2019-04-29

Published Print: 2019-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Xu, Yan

Sharma, Aditi

Chen, Yang

Zhou, Honghui
License Information

Text and Data Mining valid from 2019-04-29
More Information

Article History

First Online: 29 April 2019

Compliance with Ethical Standards

:

: Aditi Sharma was an intern of Janssen Research & Development, LLC at the time of the study; all other authors are employees of Janssen Research & Development, LLC.

: The opinions expressed in this publication are those of the authors and not necessarily those of the company that employs them.

: This article does not contain any studies with human or animal subjects performed by any of the authors.